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1. Introduction
Atypical antipsychotic drugs (APDs) such as risperidone and 
olanzapine, have been increasingly used for the treatment of anx-
iety-related disorders with mixed results (Carson and Kitagawa, 
2004). Some case reports suggest that clozapine, olanzapine, que-
tiapine and risperidone improve symptoms of obsessive–compul-
sive disorder (OCD) and panic disorder, while an equal number of 
reports indicate the worsening effects of each drug on these disor-
ders (Brooke et al., 2005). For other anxiety disorders, such as post-
traumatic stress disorder (PTSD), some studies find that atypicals 
improve certain symptoms (e.g., hyperarousal and reexperienc-
ing) (Hamner, 1996; Monnelly et al., 2003; Petty et al., 2001), while 
others failed to reach the same conclusion (Butterfield et al., 2001; 
Hamner et al., 2003).
Preclinical evidence on the intrinsic anxiolytic-like property 
of atypical antipsychotics is also inconclusive. Previous studies 
have found results that suggest an anxiolytic-like, anxiogenic-like 
or no effect on various anxiety-like measures (Ichihara et al., 1988; 
Ishida-Tokuda et al., 1996; Karl et al., 2006; Kovacs and de Wied, 
1978; Moore et al., 1994; Moore et al., 1992; Thiessen and Upchurch, 
1981; Timmerman et al., 1990). We think that at least two factors 
may contribute to this rather confusing literature. First, a wide va-
riety of behavioral models have been used in different studies, 
which may not measure the same aspects of fear/anxiety-like re-
sponses and may not provide the same assessment of the drug ef-
fects. Also, most studies employ only one behavioral task or one 
response measure of fear, rather than a series of convergent tasks 
to cross-validate the findings. Thus it is difficult to make compar-
isons across different studies. Second, there are great variations in 
the experimental designs (e.g. species, drug doses, timing of drug 
administrations, etc.), which may enhance or mask the effect size 
of one particular effect and influence data interpretation.
In a recent study (Mead et al., 2008), we evaluated the possi-
ble anxiolytic-like property of clozapine and olanzapine, and com-
pared them with the typical antipsychotic haloperidol and chlor-
diazepoxide (a prototype of sedative–anxiolytic drug). The unique 
feature of that study was that we employed two different behav-
ioral models (a fear-induced passive avoidance and conditioned 
place aversion paradigm and a two-way active avoidance condi-
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Atypical antipsychotics are also used in the treatment of anxiety-related disorders. Clinical and preclinical evidence regarding 
their intrinsic anxiolytic efficacy has been mixed. In this study, we examined the potential anxiolytic-like effects of risperidone 
and olanzapine, and compared them with haloperidol, chlordiazepoxide (a prototype of sedative–anxiolytic drug) or citalo-
pram (a selective serotonin reuptake inhibitor). We used a composite of two-way avoidance conditioning and acoustic startle 
reflex model and examined the effects of drug treatments during the acquisition phase (Experiment 1) or extinction phase (Ex-
periments 2 and 3) on multiple measures of conditioned and unconditioned fear/anxiety-like responses. In Experiment 4, we 
further compared risperidone, olanzapine, haloperidol, citalopram and chlordiazepoxide in a standard elevated plus maze 
test. Results revealed three distinct anxiolytic-like profiles associated with risperidone, olanzapine and chlordiazepoxide. Ris-
peridone, especially at 1.0 mg/kg, significantly decreased the number of avoidance responses, 22 kHz ultrasonic vocaliza-
tion, avoidance conditioning-induced hyperthermia and startle reactivity, but did not affect defecations or time spent on the 
open arms. Olanzapine (2.0 mg/kg, sc) significantly decreased the number of avoidance responses, 22 kHz vocalization and 
amount of defecations, but it did not inhibit startle reactivity and time spent on the open arms. Chlordiazepoxide (10 mg/kg, 
ip) significantly decreased the number of 22 kHz vocalization, avoidance conditioning-induced hyperthermia and amount of 
defecations, and increased time spent on the open arms, but did not decrease avoidance responses or startle reactivity. Halo-
peridol and citalopram did not display any anxiolytic-like property in these tests. The results highlight the importance of us-
ing multiple measures of fear-related responses to delineate behavioral profiles of psychotherapeutic drugs.
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tioning paradigm) and multiple measures of fear/anxiety-like re-
sponses (both behavioral as well as physiological) so that our 
results were not an artifact of a single model or measure. The con-
ditioned avoidance response model (CAR) is a fear-motivated in-
strumental conditioning model and is commonly used to study 
anti-“psychotic” activity (Bolles, 1970; Levis and Brewer, 2001; Re-
scorla and Solomon, 1967; Wadenberg and Hicks, 1999). It was 
used to study the possible anxiolytic-like effects of antipsychotics 
because animals tested in this model show various fear or anxi-
ety-like signs, such as increased body temperature, emission of ul-
trasonic vocalization (termed 22-KHz USV), and defecation and 
urination, which have been routinely used as reliable measures of 
conditioned reactive fear as well as to assess anxiolytic-like prop-
erties of psychotropic drugs (De Vry et al., 1993; Fanselow, 1986; 
Godsil et al., 2000; Sanchez, 2003). Thus we were able to use this 
single behavioral paradigm to assess both antipsychotic (as in-
dexed by anti-avoidance effect) and potential anxiolytic-like ef-
fects of antipsychotic drugs. Our results show that clozapine and 
olanzapine possess an intrinsic anxiolytic-like property, which is 
not attributable to their anti-“psychotic” effect or favorable effects 
on motor functions or learning and memory processes. Our find-
ings also suggest that the combined use of multiple models is bet-
ter in differentiating typical and atypical antipsychotics as well as 
anxiolytics.
Building on this success, we examined the potential anxiolytic-
like property of risperidone and further examined that of olan-
zapine. We employed a similar multi-measure and multi-task ap-
proach (e.g. avoidance conditioning, startle reflex, and elevated 
plus maze) and tested drugs at both the acquisition and extinc-
tion stages of avoidance conditioning. In Experiment 1, we used a 
composite of avoidance conditioning and an acoustic startle reflex 
model and examined the dose-dependent effects of risperidone, 
citalopram and chlordiazepoxide treatment during the acquisition 
phase on the avoidance response as well as on a host of other fear 
responses (amount of defecation, ultrasonic vocalization, change 
in body temperature, and fear-intensified startle reflex). In Exper-
iments 2 and 3, we used the same model and examined the effects 
of risperidone and olanzapine treatment on the extinction of vari-
ous fear-elicited responses. In Experiment 4, we used a standard 
elevated plus maze test (EPM), a more widely used animal model 
of anxiety, to cross-validate the findings from the first three exper-
iments. We also compared risperidone and olanzapine with halo-
peridol, citalopram and chlordiazepoxide in this task.
2. Materials and methods
2.1. Subjects
Male Sprague–Dawley rats (250–275 g upon arrival, Charles River, 
Portage, MI) were housed two per cage, in 48.3 cm × 26.7 cm × 20.
3 cm transparent polycarbonate cages under 12-h light/dark con-
ditions (light on between 6:00 am and 6:00 pm). Room tempera-
ture was maintained at 22 ± 1 with a relative humidity of 55–60%. 
Food and water was available ad libitum. Animals were allowed at 
least one week of habituation to the animal facility before being 
used in experiments. All procedures were approved by the animal 
care committees at the University of Nebraska-Lincoln.
2.2. Conditioned avoidance response and ultrasonic vocalization 
recording apparatus
Four identical two-way shuttle boxes custom designed and man-
ufactured by Med Associates (St. Albans, VT) were used. Each 
box was housed in a ventilated, sound-insulated isolation cubi-
cle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 64 cm 
long, 30 cm high (from grid floor) and 24 cm wide, and divided 
into two equal-sized compartments by a white PVC partition with 
an arch style doorway (15 cm high × 9 cm wide at base). An alu-
minum hurdle (4 cm high) was placed between the two compart-
ments, so the rats had to jump from one compartment to the other. 
The grid floor consisted of 40 stainless steel rods with a diame-
ter of 0.48 cm, spaced 1.6 cm apart center to center, through which 
a scrambled footshock (US, 0.8 mA) was delivered by a constant 
current shock generator (Model ENV-410B) and scrambler (Model 
ENV-412). The rat location and motor activity was detected by a 
set of 16 photobeams (ENV-256-8P) affixed at the bottom of the 
box (3.5 cm above the grid floor). Two houselights (28 V) were 
mounted at the top of each compartment. The CS was a 76 dB 
white noise produced by a speaker (ENV 224AMX) mounted on 
the ceiling of the cubicle, centered above the shuttle box. All the 
training and testing procedures were controlled by Med Associ-
ates programs running on a computer. Background noise (approx-
imately 74 dB) was provided by a ventilation fan affixed at the top 
corner of each isolation cubicle.
In each CAR box, an ultrasonic vocalization microphone (P48 
Avisoft Bioacoustics/Emkay Microphone, Avisoft Bioacoustics, 
Berlin, Germany) was mounted on the ceiling of the two-compart-
ment chamber. The microphone was connected via an E-MU 0404 
USB Audio device to a computer. Acoustic data were displayed 
in real time by the Avisoft RECORDER, a multi-channel trigger-
ing hard-disk recording software (version 3.4; Avisoft Bioacous-
tics), and were recorded at a sampling rate of 192 kHz in 16 bit 
format and analyzed by Avisoft SASLab Pro (version 4.51; Avisoft 
Bioacoustics).
2.3. Acoustic startle reflex apparatus
Four startle monitor systems (Kinder Scientific, Julian, CA), 
controlled by a PC were used as the testing apparatus. They 
were housed in compact sound attenuation cabinets (35.56 cm 
wide × 27.62 cm deep × 49.53 cm high). A speaker (diame-
ter: 11 cm) mounted on the cabinet’s ceiling was used to gener-
ate acoustic stimuli (70 dB–120 dB white noise). The startle activ-
ity was measured by a piezoelectric sensing platform on the floor. 
During testing, rats were placed in a rectangular box made of 
transparent Plexiglas (19 cm wide × 9.8 cm deep × 14.6 high) with 
an adjustable ceiling, providing only limited restraint while pro-
hibiting ambulation.
2.4. Elevated plus maze apparatus
The elevated plus maze (EPM) was situated in a room with 
an illuminance of about 52 lx. It consisted of two open arms 
(50 cm×10 cm), two enclosed arms (50 cm×10 cm) and a central 
platform (10 cm×10 cm) made of black polycarbonate plastic. Each 
arm was supported by a sturdy plastic leg and was elevated 50 cm 
above the floor. The two enclosed arms had high walls (38.5 cm 
in height), while the two open arms had raised edges (1.0 cm in 
height) along each side and end to decrease the possibility of fall-
ing during drug testing (Fernandes and File, 1996). Behavior was 
digitally recorded on a computer located in an adjacent room and 
automatically scored via Biobserve Viewer video tracking soft-
ware (Biobserve, Germany).
2.5. Drugs
The injection solutions of haloperidol (HAL, 5.0 mg/ml ampoules, 
Sicor Pharmaceuticals, Inc, Irvine, CA) and chlordiazepoxide (CDP, 
Sigma-Aldrich, St. Louis, MO) were obtained by mixing drugs with 
sterile water. Olanzapine (OLZ, Toronto Research Chemicals Inc, 
Ontario, Canada) and risperidone (RIS, a gift from the NIMH drug 
supply program) were dissolved in 1.0–1.5% glacial acetic acid in 
sterile water. Citalopram (CIT, Toronto Research Chemicals Inc., 
Ontario, Canada) was dissolved in 0.9% physiological saline.
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2.6. Experiment 1: Effects of risperidone, chlordiazepoxide and 
citalopram treatment during the acquisition phase of a composite 
CAR and startle reflex task on various fear/anxiety-like responses
Forty-eight rats were first habituated to the CAR boxes and star-
tle boxes for 3 consecutive days (20 min in each box/day). On 
each habituation day, 1 h after injection of sterile water, rats were 
placed in the CAR boxes. The number of 22 kHz USV and amount 
of defecation (in mg) in the CAR boxes were recorded. Body tem-
perature was measured using a probe (lubricated with mineral oil) 
inserted in the rectum (Thermalert TH-5, Physitemp, Clifton, NJ, 
USA) immediately before and after the CAR box exposure (20 min 
interval). Then, they were placed in the startle reflex boxes and ex-
posed to the background noise (70 dB) for 20 min before being re-
turned to their home cages.
After the habituation, they were randomly assigned to 6 groups 
(n = 8/group): vehicle (sterile water), RIS 0.2 mg/kg, 0.33 mg/kg, 
1.0 mg/kg, CDP 10.0 mg/kg or CIT 10.0 mg/kg, and trained/tested 
under drug for 7 consecutive days, followed by 3 drug-free tests. 
We tested three doses of RIS, which covered subclinical, clinical and 
superclinical doses in terms of D2 receptor occupancy (50%–80%) to 
explore its dose-dependent effect (Kapur et al., 2003). CDP and CIT, 
two non-antipsychotic drugs were included as comparisons (Griebel 
et al., 1994; Mead et al., in press; Sanchez, 2003). Each daily drug test 
consisted of two components: a 20-trial two-way CAR session and 
a startle session. Rats were first injected with RIS, CDP, CIT or ve-
hicle, and their body temperature was measured 0.5 h (in the case 
of CDP) or 1 h later (in the case of other treatments) (Mead and Li, 
in press). Then, they were placed in the CAR boxes and trained for 
20 trials. Each trial started by presenting a white noise (CS) for 10 s, 
followed by a continuous scrambled footshock (0.8 mA, US, maxi-
mum 5 s) on the grid floor. If a subject moved from one compart-
ment into the other within the 10 s of CS presentation, it avoided 
the shock, and this shuttling response was recorded as avoidance. 
If the rat remained in the same compartment for more than 10 s and 
made a crossing upon receiving the footshock, this response was re-
corded as escape. If the animal did not respond during the entire 5 s 
presentation of the shock, the trial was terminated and escape fail-
ure was recorded. Intertrial intervals varied randomly between 30 s 
and 60 s (mean = 45 s). The number of avoidance responses (max: 
20) was calculated as the main dependent variable for avoidance re-
sponding. Fecal matter was collected at the end of CAR session and 
weighed on a Mettler Toledo scale (< 0.1 mg). Ultrasonic vocaliza-
tions at the 22 kHz range (20–32 kHz) were recorded using Avisoft 
Recorder software (Version 3.4). Settings included sampling rate 
at 192 kHz, format 16 bit. For acoustical analysis, recordings were 
transferred to Avisoft SASLab Pro (Version 4.51) and a fast Fou-
rier transformation (FFT) was conducted. Spectrograms were gen-
erated with an FFT-length of 256 points and a time window over-
lap of 50% (100% Frame, FlatTop window). The spectrogram was 
produced at a frequency resolution of 750 Hz and a time resolu-
tion of 0.6667 ms. Call detection was provided by an automatic sin-
gle threshold-based algorithm (threshold: −20 dB) and a hold-time 
mechanism (hold-time: 0.02 s).
Immediately after the rats completed the CAR component of 
testing, they were placed in the acoustic startle boxes and tested 
for startle responses under 6 trial conditions (Davis, 1986; Walker 
and Davis, 2002). During the 5 min acclimation period (background 
noise set at 70 dB), activity was sampled for 100 ms every 60 s. Af-
ter the acclimation period, 15 startle-eliciting stimuli (leaders) were 
given in a pseudorandom order, five at each of three different in-
tensities (95, 100, and 105 dB, 50 ms in duration). The leaders were 
used to familiarize the rats to the acoustic stimuli and were not 
used for statistical analysis. Following the leaders, another 30 startle 
stimuli were presented, five for each type at three dB levels (95 dB, 
100 dB, 105 dB alone; 76 dB + 95 dB, 76 dB + 100 dB, 76 dB + 105 dB) 
with a 30 s intertrial interval. For the 95 dB, 100 dB and 105 dB 
alone trials, startle activity was sampled for 50 ms immediately af-
ter the white startle noise (95, 100, or 105 dB) was presented. For the 
76 dB + 95 dB, 76 dB + 100 dB, 76 dB + 105 dB trials, a 76 dB white 
noise was presented first for 3.2 s, followed 10 ms later by one of 
the white startle noises (95, 100, or 105 dB) for 50 ms. Again, startle 
activity was sampled for 50 ms immediately after the white startle 
noise (95, 100, 105 dB) was presented. This 76 dB white noise was 
identical to the CS used in the CAR. It was hypothesized that startle 
activity under this condition encompasses an acquired fear compo-
nent (“conditioned fear”), whereas startle activity under the startle 
noise-alone condition reflects an innate fear (“unconditioned fear”). 
Whole body startle responses were recorded in Newtons.
One day after the last training session, all rats were continu-
ously tested drug-free for an additional 3 sessions under the CS-
alone (no shock) condition. The procedure described above was 
employed identically except that the footshock was omitted.
2.7. Experiment 2: Effects of risperidone treatment (1.0 mg/kg) on 
the extinction of various fear/anxiety-like responses in the CAR-
trained rats
Experiment 1 showed that RIS at 1.0 mg/kg exhibited a robust 
and consistent anxiolytic-like effect in the rats that were trained 
in the CAR. This experiment examined whether RIS at 1.0 mg/kg 
also exhibits a robust anxiolytic-like effect in rats that had already 
acquired avoidance behavior.
Thirty-six rats were first habituated to the CAR boxes for 2 days 
(20 min/day). Then, they were trained in the CAR for 10 sessions. 
The first 9 sessions used 20 trials, while the last session used 30 tri-
als, in which the number of 22 kHz USV and amount of defeca-
tion were also recorded. Rats were then semi-randomly assigned to 
one of four groups matched for avoidance performance on the last 
training day (baseline): VEH-I (water, sc, n = 9), VEH-D (water, sc, 
n = 9), RIS-I (1.0 mg/kg, sc, n = 9) and RIS-D (1.0 mg/kg, sc, n = 9) 
and tested daily 1 h after RIS or vehicle treatment under the CS-only 
(no shock, 30 trials/daily session) condition for 3 consecutive days. 
In each test, the CS was immediately terminated after a rat made an 
avoidance response for rats in the VEH-I and RIS-I conditions (“I” 
stands for “Immediate”), or the CS remained on for another 5 sec-
onds after a rat made an avoidance response for rats in the VEH-D 
and RIS-D conditions (“D” stands for “Delayed”). This delayed CS 
condition is known to cause increased fear and facilitate avoidance 
decline in the CAR-trained rats (Bolles and Grossen, 1970; Kamin, 
1956). Each daily test began 60 min after RIS or vehicle administra-
tion, and each test session consisted of 30 trials. Immediately after 
being taken out from the CAR boxes, rats were placed in one of four 
startle boxes for startle activity testing. One day after the 3 days of 
drug testing, rats were tested drug-free in two additional CS-only 
sessions (30 trials/session) to examine the post-treatment effect.
2.8. Experiment 3: Effects of olanzapine treatment (2.0 mg/kg) on 
the extinction of various fear/anxiety-like responses in the CAR-
trained rats
This experiment was identical to that of Experiment 2 with a cou-
ple of exceptions. First, 40 rats instead of 36 were used. Second, 
OLZ at 2.0 mg/kg was tested. Our previous work shows that 
when administrated during the acquisition phase of CAR, OLZ at 
2.0 mg/kg significantly inhibited the body temperature increase 
and fear-induced defecation (Mead and Li, in press). This work 
further investigated the anxiolytic-like effect of OLZ on the extinc-
tion of various fear-elicited responses.
2.9. Experiment 4: Effects of risperidone, olanzapine, haloperidol, 
chlordiazepoxide and citalopram treatment on an elevated plus 
maze test
Rats were first handled for two days (2 min/day/rat). On the test-
ing day, they were first injected with RIS (0.33 or 1.0 mg/kg, sc, 
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n = 8/group), OLZ (0.5 or 1.0 mg/kg, sc, n = 9 and 8 respectively), 
HAL (0.03 or 0.05 mg/kg, sc, n = 8 and 9 respectively), CIT (10 mg/
kg, sc, n = 10), CDP (10 mg/kg, ip, n = 18) or vehicle (sterile water, 
n = 18). One hour later (or 0.5 h later for CDP rats), rats were indi-
vidually placed in the central part of the maze facing one of the en-
closed arms. The numbers of entries made into enclosed and open 
arms and time spent in enclosed and open arms were automatically 
recorded for 5 min using a video tracking system (Biobserve, Ger-
many). An arm entry was defined as all four paws being placed on 
an arm. The subjects were run in batches, with a requirement that 
each batch contained at least 2 vehicle and two CDP controls. RIS 
and OLZ were assessed first, followed by tests on HAL and CIT.
2.10. Statistical analysis
Data were expressed as mean values ± SEM and were analyzed us-
ing a factorial repeated measures analysis of variance (ANOVA) 
with the between-subjects factor being treatment and/or group 
condition (e.g. RIS vs. VEH, immediate CS vs. delayed CS, etc.) and 
the within-subject factor being the test sessions (e.g. day 1 test, day 
2 test, etc.) or test conditions (e.g. startle levels). Post hoc LSD tests 
were used to identify any possible drug treatment effect in compar-
ison to vehicle control. To examine group difference on specific test 
days, one-way ANOVAs and post hoc tests were used. A conven-
tional two-tailed level of significance at the 5% level was required.
3. Results
3.1. Experiment 1: Effects of risperidone, chlordiazepoxide and 
citalopram treatment during the acquisition phase of a composite 
CAR and startle reflex task on various fear/anxiety-like responses
3.1.1. Avoidance response — Repeated measures ANOVA re-
vealed a main effect of “treatment” (F(5,42) = 8.671, p < 0.001), 
“session” (F(6,252) = 47.202, p < 0.001) and a significant 
“treatment” × “session” interaction (F(30,252) = 3.555, p < 0.001). 
Post hoc tests indicated that only the RIS 1.0 mg/kg group differed 
significantly from the vehicle group (p < 0.001). Rats treated with 
CDP (10 mg/kg), CIT (10 mg/kg), RIS (0.2 and 0.33 mg/kg) or ve-
hicle (distilled water) all showed a steady improvement in avoid-
ance responding. On the three subsequent drug-free CS-only test 
days, once again, only the RIS 1.0 group still showed significantly 
fewer avoidance responses than the other drug groups (p < 0.001). 
These data were originally reported as Figure 4 in Mead and Li (in 
press) for the purpose of studying the behavioral mechanisms of 
antipsychotic action in the CAR. None of the following data was 
reported before.
3.1.2. 22 kHz USV — During the 7 CAR training days, the number 
of USV showed a progressive decline (F(6,252) = 21.179, p < 0.001; 
Figure 1). RIS (1.0 mg/kg) and CDP (10 mg/kg) decreased the 
number of 22 kHz USV in comparison to the vehicle treatment (a 
significant “treatment” × “session” interaction, F(30,252) = 2.299, 
p < 0.001). One-way ANOVAs on each CAR training day showed 
that RIS (1.0 mg/kg) was significantly different from the vehi-
cle on day 1 (p = 0.020), day 2 (p = 0.010), day 3 (p = 0.014), day 
4 (p = 0.040), and day 7 (p = 0.035). CDP (10 mg/kg) was sig-
nificantly different from the vehicle on day 4 (p = 0.027), day 5 
(p = 0.048), and day 7 (p = 0.040). On the 3 drug-free CS-only test 
days, all groups exhibited fewer USV and no group difference 
was detected (“treatment”: F(5,42) = 1.531, p = 0.201; “session”: 
F(2,84) = 2.445, p = 0.093; “treatment” × “session” interaction, 
F(10,84) = 0.714, p = 0.709).
3.1.3. Defecations and body temperature change — During the habitu-
ation days, both measures remained low, and no significant group 
difference was detected (all ps > 0.05). During the CAR training 
phase, RIS (0.2, 1.0 mg/kg) and CDP (10 mg/kg) significantly de-
creased the avoidance conditioning-induced increase in body tem-
perature (RIS 0.2 vs. VEH, p = 0.050; RIS 1.0 vs. VEH, p = 0.005; 
CDP vs. VEH, p = 0.017, data not shown). CDP, but not RIS or CIT, 
also significantly decreased the amount of defecation (p = 0.019). 
During the drug-free test phase, the effects of RIS and CDP were 
no longer present (all ps > 0.05, data not shown). Interestingly, the 
RIS (1.0 mg/kg) rats defecated significantly more than the vehicle 
rats (p = 0.020), indicating a drug-withdrawal-induced rebound.
3.1.4. Startle responses — To simplify data presentation, we first 
averaged each rat’s startle activity data under the three startle-
alone conditions (95 dB, 100 dB, 105 dB alone) and three CS + star-
tle conditions (76 dB + 95 dB, 76 dB + 100 dB, 76 dB + 105 dB) 
separately. We then calculated the percent changes in the av-
erage startle activity for each rat from the pre-CAR day (i.e. the 
3rd and last habituation day) to each of 7 drug test days and 3 
drug-free test days. Finally, we averaged the percent changes for 
the 7 drug days and 3 drug-free days separately. Results are pre-
sented in Figure 2. During the drug test phase, RIS, but not CDP 
or CIT, suppressed the percent change of the mean startle activity 
from the baseline, and this suppressive effect of RIS disappeared 
when the drug treatment stopped. On the drug testing data, re-
peated measures ANOVA (drug treatment as a between-subjects 
factor and startle testing conditions (i.e. startle-alone or CS + star-
tle) as a within-subjects factor) revealed a main effect of “testing 
condition” (F(1,42) = 5.491, p = 0.024), “treatment” (F(5,42) = 4.764, 
p = 0.002), but no significant “testing condition” × “treatment” in-
Figure 1. Mean (+ SEM) numbers of 22 kHz ultrasonic vo-
calization (A) that the rats made throughout the habitua-
tion, seven CAR training days and three drug-free test 
days. *p < 0.05 significantly different from the vehicle 
group. 
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teraction (F(5,42)=1.348, p = 0.263). One-way ANOVAs on group 
differences indicated that the three RIS groups differed signifi-
cantly from the vehicle group only under the CS + startle con-
ditions (p = 0.012, 0.023 and 0.005 for RIS 0.2, 0.33 and 1.0 mg/
kg respectively), but not under the startle-alone conditions (all 
ps > 0.05). To the extent that startle activity under the CS + startle 
conditions reflects an acquired fear (“conditioned fear”), whereas 
startle activity under the startle-alone condition reflects an innate 
fear (“unconditioned fear”), this result suggests that RIS may pref-
erentially inhibit conditioned fear over unconditioned fear. Dur-
ing the drug-free test phase, the RIS treatment effect was no lon-
ger present (p > 0.05).
3.2. Experiment 2: Effects of risperidone treatment (1.0 mg/kg) on 
the extinction of various fear/anxiety-like responses in the CAR-
trained rats
3.2.1. Avoidance response — Figure 3A shows the number of condi-
tioned avoidance responses in the four groups over the three phases 
(baseline, three drug test days and two drug-free days). RIS (1.0 mg/
kg) significantly suppressed avoidance responding (F(1,32) = 85.787, 
p < 0.001), and the delayed termination of CS also caused a progres-
sive decline in avoidance responding (F(1,32) = 4.645, p = 0.0390) 
during the drug test days. There was also a significant 3-way in-
teraction among “treatment”, “condition” and “test day” (days 1, 
2 and 3) (F(2,64) = 6.328, p = 0.003). No group difference during the 
two drug-free test days was detected (ps > 0.05).
3.2.2. 22 kHz USV and defecations — During the drug test phase, RIS 
significantly decreased the number of 22 kHz vocalization calls in 
the well-trained rats (a main effect of “treatment: F(1,32) = 6.335, 
p = 0.017, Figure 3B), but did not decrease the amount of defeca-
tion (F(1,32) = 2.329, p = 0.137, Figure 3C). These findings were 
consistent with what we observed in Experiment 1. The CS test-
ing condition did not impact both measures of fear (22 kHz 
USVs: F(1,32) = 0.191, p = 0.665; defecations: F(1,32) = 0.107, 
p = 0.746), nor did it interact with the RIS treatment on these 
measures (22 kHz USVs: F(1,32) = 0.332, p = 0.569; defecations: 
F(1,32) = 1.695, p = 0.202). No treatment effect or testing condition 
effect was present on the drug-free test days (ps > 0.05).
3.2.3. Startle responses — RIS significantly decreased the mean per-
cent startle activity change from the pre-drug day (the last CAR 
training day) to the drug test days (Figure 3D). There was a sig-
nificant main effect of “treatment” (F(1,32) = 9.581, p = 0.004), but 
no main effect of CAR testing condition (immediate vs. delayed 
CS, p = 0.59). No significant interaction effect was found (p > 0.59). 
The mean percent startle activity change was also not affected by 
the startle testing conditions (i.e. the CS + startle or startle-alone 
condition) (F(1,32) = 0.618, p = 0.438). One-way ANOVAs on the 
group differences indicated that the two RIS groups differed sig-
nificantly from the two vehicle groups, mainly under the CS + star-
tle conditions (ps = 0.019–0.049), again suggesting that RIS prefer-
entially inhibits startle activity that encompasses a conditioned 
fear component. The RIS-I group also showed a significant dif-
ference from the VEH-I group under the startle-alone condition 
(p = 0.019). The RIS effect disappeared when the drug treatment 
stopped as no significant effect with “treatment”, “testing condi-
tion” or their interactions was found (Figure 3E, all ps > 0.05).
3.3. Experiment 3: Effects of olanzapine treatment (2.0 mg/kg) on 
the extinction of various fear/anxiety-like responses in the CAR-
trained rats
3.3.1. Avoidance response — Figure 4A shows the number of con-
ditioned avoidance responses in the four groups over the 
three phases (baseline, three drug test days and two drug-free 
days). OLZ (2.0 mg/kg) significantly suppressed avoidance re-
sponding (F(1,36) = 40.618, p < 0.001), and the delayed termi-
nation of CS also caused a decrease in avoidance responding 
(F(1,36) = 5.05, p = 0.031). There was also a main effect of “test day” 
(F(2,72) = 7.439, p = 0.001), and a significant “treatment” × “test 
day” interaction (F(2,72) = 3.392, p = 0.039). There was no group 
difference during the two drug-free test days (ps > 0.4).
3.3.2. 22 kHz USV and defecations — During the drug test phase, 
OLZ significantly decreased the number of 22 kHz calls (a main 
effect of “treatment: F(1,36) = 5.715, p = 0.022, Figure 4B) and the 
amount of defecation (F(1,36)=12.513, p = 0.001, Figure 4C) in the 
well-trained rats. The CS testing condition did not impact both 
measures of fear (22 kHz USVs: F(1,36) = 0.439, p = 0.512; def-
ecations: F(1,36) = 0.738, p = 0.396), nor did it interact with the 
OLZ treatment on these measures (22 kHz USVs: F(1,36) = 0.637, 
p = 0.430; defecations: F(1,36) = 1.504, p = 0.228). No treatment ef-
fect or testing condition effect was present during the drug-free 
test phase (all ps > 0.05).
3.3.3. Startle responses — During the drug test phase, OLZ at 2.0 mg/
kg did not significantly decrease the mean percent startle activity 
change (Figure 4D). There was no significant main effect of “treat-
ment” (F(1,36) = 1.723, p = 0.198), no main effect of CAR testing 
condition (immediate vs. delayed CS, F(1,36) = 2.105, p = 0.155) or 
their interaction (F(1,36) = 0.374, p = 0.545). However, the mean per-
cent startle activity change was significantly affected by the startle 
testing conditions (i.e. the CS + startle or startle-alone condition) 
(F(1,36) = 25.847, p < 0.001), with rats showing less decrease under 
the startle-alone condition than under the CS + startle condition. 
During the drug-free test phase, no significant treatment or CAR 
testing condition was found (Figure 4E, all ps > 0.05).
Figure 2. Mean (+ SEM) percent change from the baseline (the pre-
drug day) to the drug test days of the averaged startle activity un-
der the CS + startle conditions (i.e., 76 dB + 95 dB, 76 dB + 100 dB, 
76 dB + 105 dB) and the startle-alone conditions (i.e., 95 dB, 100 dB, 
105 dB alone) (A) and drug-free test days (B). *p < 0.05 significantly 
different from the vehicle group. 
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3.4. Experiment 4: Effects of risperidone, olanzapine, haloperidol, 
chlordiazepoxide and citalopram treatment on an elevated plus 
maze test
During the test, 1 rat in the CDP group and 1 rat in the OLZ 
1.0 mg/kg fell off from the maze, and their data were not in-
cluded in the analysis (Walf and Frye, 2007). A repeated mea-
sures ANOVA on the time spent on the open arms (a within-
subjects factor) revealed a significant effect of “treatment” 
(F(8,85) = 2.137, p = 0.041), “arm” (F(1,85) = 111.248, p < 0.001) 
and “treatment” × “arm” interaction (F(8,85) = 3.252, p = 0.003). 
Similar analysis on the entries to the open arms also revealed 
a significant effect of “treatment” (F(8,85) = 2.573, p = 0.015), 
“arm” (F(1,85) = 53.718, p < 0.001) and “treatment” × “arm” 
interaction (F(8,85) = 3.154, p = 0.004), suggesting that differ-
ent drug treatments differentially affected time spent on the 
open and closed arms and the number of entries to the open 
and closed arms. One-way ANOVAs showed that only CDP 
(10.0 mg/kg) significantly increased time spent on the open 
arms (Figure 5A, ps = 0.011 vs. VEH). In addition, OLZ (1.0 mg/
kg), RIS (1.0 mg/kg) and HAL (0.05 mg/kg) significantly de-
creased the number of entries to the open arms (Figure 5B, 
ps = 0.013, 0.02 and 0.049 respectively), suggesting a possible 
motor impairment effect.
Figure 3. Mean (+ SEM) numbers of avoidance responses (A), 22 kHz USV counts (B), amount of defecations (C), percent change of the averaged 
startle activity under the CS + startle and the startle-alone conditions from the baseline to the drug days (D), and to the drug-free days (E) of the 
four groups of rats that were treated with risperidone (1.0 mg/kg, sc) or vehicle (sterile water) and tested under the immediate CS termination 
(RIS-I and VEH-I) or the delayed CS termination condition (RIS-D and VEH-D). *p < 0.05 significantly different from the vehicle group. 
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4. Discussions
Table 1 summarizes the effects of risperidone, olanzapine and chlor-
diazepoxide treatment on various fear and anxiety-like responses 
found in the present study. Three distinct anxiolytic-like profiles 
are apparent. Risperidone (1.0 mg/kg, sc) was efficacious against 
an increase in 22 kHz USV, body temperature, and startle reactivity 
elicited by conditioned fear, but was ineffective in decreasing the 
amount of defecations and increasing time spent on the open arms. 
Olanzapine (2.0 mg/kg, sc) was efficacious against an increase in 
22 kHz USV and amount of defecations induced by fear, but was in-
effective in decreasing startle reactivity and time spent on the open 
arms. Chlordiazepoxide (10 mg/kg, ip) was efficacious against an 
increase in 22 kHz USV, body temperature, and amount of defeca-
tions. It also increased time spent on the open arms, but was inef-
fective in decreasing startle reactivity. This study, together with our 
previous report (Mead and Li, in press), and others (Moore et al., 
1994; Moore et al., 1992; Wiley et al., 1993), strongly suggests that ris-
peridone and olanzapine possess an anxiolytic-like property. Our 
results also indicate that haloperidol and citalopram, at least upon 
acute administration, did not seem to possess any anxiolytic-like 
properties, as seen in these fear/anxiety-like measures.
Figure 4. Mean (+ SEM) numbers of avoidance responses (A), 22 kHz USV counts (B), amount of defecations (C), percent change of the averaged 
startle activity under the CS + startle and the startle-alone conditions from the baseline to the drug days (D), and to the drug-free days (E) of the 
four groups of rats that were treated with olanzapine (2.0 mg/kg, sc) or vehicle (sterile water) and tested under the immediate CS termination 
(OLZ-I and VEH-I) or the delayed CS termination condition (OLZ-D and VEH-D). *p < 0.05 significantly different from the vehicle group. 
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Our results highlight the importance of using multiple mea-
sures of fear/anxiety-like responses from several animal models 
to delineate behavioral profiles of psychotherapeutic drugs. As 
our results show, no two drugs are the same. A drug may be effi-
cacious in lowering levels of fear shown in some measures but not 
in others. Therefore, it is insufficient to rely on a single measure of 
fear or anxiety-like behavior to determine an anxiolytic-like pro-
file of a drug. With multiple measures of fear/anxiety-like behav-
ior, we not only determined that risperidone and olanzapine have 
an anxiolytic-like property, but also shed light against which as-
pects of fear or anxiety-like responses that risperidone, olanzap-
ine or chlordiazepoxide is most effective. This work may be po-
tentially useful in helping better understand the neural basis of 
the specific drug effects given the fact that each measurement of 
fear or anxiety-like responses (body temperature, ultrasonic vocal-
izations, defecation and urination) may be subserved by a distinct 
pathway from the central amygdala to a variety of brainstem re-
gions (Davis and Whalen, 2001).
The present study extended our previous work (Mead and Li, in 
press) in the following three directions. First, we examined risper-
idone, another widely prescribed second generation antipsychotic 
drug with a billion dollar revenue comparable to that of olanzap-
ine. Second, we examined risperidone at both the acquisition and 
extinction phases of avoidance conditioning, and olanzapine at the 
extinction phase. Mead et al. (2008) only examined olanzapine at the 
acquisition phase. In Mead et al. (2008), we did not observe any de-
creasing effect of olanzapine on 22 kHz USV, whereas in the present 
study we did. This discrepancy may be due to the methodological 
differences. In Mead et al. (2008), olanzapine was given to rats that 
still experienced footshock at the acquisition phase, whereas in the 
present study, olanzapine was given to rats that were tested with 
only the CS at the extinction phase. Thus, the 22 kHz USV in Mead 
et al. (2008) still consisted of those that were elicited by footshock 
(an unconditioned fear), on which olanzapine may be less effec-
tive. Siemiatkowski et al. (2001) also reported that acute treatment 
with olanzapine (1.0 mg/kg, ip) reduced the pre-shock contextual 
22 kHz USV (a measurement of a “conditioned fear”) but not the 
shock-elicited ultrasonic vocalizations. These findings suggest that 
olanzapine may be less effective against measurements of uncondi-
tioned fear than those of conditioned fear, a notion supported by its 
lack of effects on the EPM and startle reflex task (see below), and on 
the open field and holeboard test (Frye and Seliga, 2003).
Third, we incorporated an acoustic startle reflex test compo-
nent in the two-way conditioned avoidance task. In each acous-
tic startle test, the rats were tested under both CS + startle and 
startle-alone conditions, reflecting putative “conditioned fear” 
and “unconditioned fear” respectively. Our results indicate that 
risperidone preferentially inhibits the conditioned fear-elicited 
startle reactivity over the innate fear-elicited one, whereas olan-
zapine does not inhibit either component. These profiles of ris-
peridone and olanzapine are consistent with clinical (Wynn et al., 
2007) and preclinical work (Le Pen and Moreau, 2002; Moore et al., 
1994; Swerdlow et al., 1996; Wiley et al., 1993) showing that risper-
idone and olanzapine generally do not decrease startle reactivity 
under the startle-alone conditions. These results are also consis-
tent with the findings from the EPM test (Experiment 4) in which 
both risperidone and olanzapine did not affect the time spent and 
number of entries to the open arms, two measures of “uncondi-
tioned” fear/anxiety-like behavior (Walf and Frye, 2007). We are 
not aware of any previous work that has investigated the risperi-
done effect on the EPM. Our finding of olanzapine on the EPM is 
consistent with a recent study showing that olanzapine (0.5 mg/
kg, ip) has little effect on anxiety-like behavior in the EPM test in 
normal rats, but shows an attenuation effect only in rats that have 
received an inescapable stress prior to the test on EPM (Locchi et 
al., 2008). However, this finding was inconsistent with that of Frye 
and Seliga (2003) who reported that olanzapine (5.0 or 10.0 mg/
kg, ip) significantly increased time on the open arms. This differ-
ence may simply be due to dose differences. It is possible that only 
at a much higher dose does olanzapine exhibit an anxiolytic-like 
effect in the EPM. Because olanzapine at 1.0 mg/kg was effective 
on several measures of conditioned fear (e.g., CS-elicited 22 kHz 
USV, body temperature change, and defections), the EPM studies 
may indicate that in order to inhibit unconditioned fear (as mea-
Figure 5. Mean (+ SEM) time in seconds spent on the open and closed 
arms (A) and mean numbers of entries to the open and closed arms 
(B) of the rats that were treated with various doses of risperidone (0.33 
or 1.0 mg/kg), olanzapine (0.5 or 1.0 mg/kg), haloperidol (0.03 or 
0.05 mg/kg), chlordiazepoxide (10 mg/kg), citalopram (10 mg/kg), or 
vehicle (sterile water). *p < 0.05 significantly different from the vehi-
cle group. 
Table 1. Summary of the effects of risperidone, olanzapine and chlordiazepoxide treatment on various fear and anxiety-like responses.
                                      22 kHz USV    Defecation      Body temperature            Startle reflex             Open arm time            Active avoidance  
                                                                                              increase                                                                     in EPM                     responding
Risperidone ↓ _ ↓ ↓ – ↓
Olanzapine ↓ ↓ ↓* – – ↓
Chlordiazepoxide ↓ ↓ ↓ – ↑ –
“ ↑ ”: denotes a significant increasing effect. “ ↓ ” : denotes a significant decreasing effect.
“ _ ” denotes no effect. “ * ”: the finding obtained from Mead et al. (2008).
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sured in the EPM), a much higher dose of olanzapine may be re-
quired. More studies are needed to further determine whether ris-
peridone and olanzapine at clinical relevant doses (Kapur et al., 
2003) are truly more efficacious against conditioned fear versus 
unconditioned fear.
The neurobiological mechanism(s) of the anxiolytic-like ac-
tion of olanzapine has implicated allopregnanolone, a metabolite 
of progesterone as an important molecule (Frye and Seliga, 2003; 
Ugale et al., 2004). Marx et al. (2006b; 2003) found that olanzap-
ine can dose-dependently increase allopregnanolone in the rat 
cerebral cortex and hippocampus (Marx et al., 2006a; Marx et al., 
2006b; Marx et al., 2003). Frye and Seliga (2003) also found that 
olanzapine’s anxiolytic-like effect coincides with its enhancing ac-
tion on brain allopregnanolone (Frye and Seliga, 2003). Since allo-
pregnanolone acts as a positive modulator of the GABAA receptor 
(Majewska, 1990) and shows a strong anxiolytic-like effect in the 
EPM task and the Geller–Seifter conflict test (Akwa et al., 1999; Bi-
tran et al., 2000; Brot et al., 1997), it is therefore possible that olan-
zapine-induced elevations in allopregnanolone may contribute to 
their anxiolytic-like effect. On the other hand, the neurobiological 
mechanisms that mediate the anxiolytic-like action of risperidone 
are less clear. Because risperidone has a complex multiple-recep-
tor binding profile, with higher affinities for D2, D3, and 5-HT2A, 
5-HT7 receptors but weaker affinities to D4, 5-HT6, histaminic H1, 
and muscarinic m1 receptors (Horacek et al., 2006; Miyamoto et al., 
2005; Seeman, 2006), it is difficult to pinpoint which receptor ac-
tion or actions account for its anxiolytic-like action. Since risperi-
done’s antagonist action on 5-HT2A receptors has been suggested 
to be important for the improved therapeutic effects of risperi-
done on negative symptoms of schizophrenia, it is possible that 
risperidone may exhibit an anti-anxiety-like effect by antagoniz-
ing 5-HT2A receptors, especially the ones located on glutamatergic 
pyramidal neurons and GABAergic interneurons in the cortex and 
hippocampus (Meltzer et al., 2003). Future research should direct 
attention to test this hypothesis.
In summary, the present study demonstrates that atypical 
APDs such as risperidone and olanzapine do possess an anxio-
lytic-like efficacy in addition to their antipsychotic efficacy. This 
additional efficacy is different from that of chlordiazepoxide, a tra-
ditional anxiolytic drug. Our findings are important because they 
can be utilized to develop methods of ameliorating anxiety or fear 
in schizophrenics (Blin et al., 1996) and provide some guidelines 
on which drug to use for different manifestations (e.g., behavioral, 
emotional, and physiological, etc.) of anxiety symptoms.
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